Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
130
Recruiting, industry sponsors, Neurology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting130
- Completed1,020
130 trials
Showing 1 to 25, recently updated first.
Aeovian Pharmaceuticals, Inc.Industry
NCT07680322 · 42 participants (planned) · Start Oct 5, 2026 · Primary completion Sep 1, 2027
Drug: AV078; Placebo · For: Tuberous Sclerosis Complex; Epilepsy
Sites: London, Canada
- A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's DiseasePivotal-lookingRecruiting
Biohaven Therapeutics Ltd.Industry
NCT06976268 · 550 participants (planned) · Start May 28, 2025 · Primary completion Aug 2027
Drug: BHV-8000 10mg; BHV-8000 20 mg and 1 more · For: Parkinson Disease
Sites: Birmingham, Alabama; Sun City, Arizona; Irvine, California · 26 sites in all
argenxargenx (ARGX)
NCT07760818 · 75 participants (planned) · Start Oct 9, 2026 · Primary completion Jul 28, 2028
Drug: efgartigimod PH20 SC · For: Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies
Sites: Sarasota, Florida; Tampa, Florida; Sterling Heights, Michigan
- A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsPivotal-lookingRecruiting
Arvinas Inc.Industry
NCT07749586 · 499 participants (planned) · Start Jul 29, 2026 · Primary completion Mar 31, 2031
Drug: ARV-6723; Pembrolizumab and 1 more · For: Advanced Solid Tumor
Sites: Boston, Massachusetts; New York, New York; Huntersville, North Carolina · 5 sites in all
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
- A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresRecruiting
Rapport Therapeutics Inc.Industry
NCT07219407 · 30 participants (planned) · Start Dec 15, 2025 · Primary completion Feb 3, 2028
Drug: RAP-219 · For: Focal Epilepsy; Epilepsy; Refractory Focal Epilepsy and 3 more
Sites: Boise, Idaho; Rochester, Minnesota; New York, New York · 7 sites in all
Faeth TherapeuticsIndustry
NCT07558733 · 32 participants (planned) · Start Apr 22, 2026 · Primary completion May 2029
Drug: Serabelisib; Sapanisertib and 1 more · For: HR+ HER2- Breast Cancer
Sites: Los Angeles, California; Newport Beach, California; Lone Tree, Colorado · 9 sites in all
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
NCT07176286 · 20 participants (planned) · Start Apr 30, 2026 · Primary completion Mar 30, 2027
Drug: 18F-MFBG · For: Parkinson Disease (PD); Lewy Body Dementia (LBD)
Sites: Houston, Texas
argenxargenx (ARGX)
NCT07673627 · 40 participants (planned) · Start Jul 10, 2026 · Primary completion Oct 2027
Drug: Empasiprubart IV · For: AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG); MG - Myasthenia Gravis and 1 more
Sites: Carlsbad, California; Miami, Florida; Tampa, Florida · 19 sites in all
AllRock Bio, Inc.Industry
NCT07175038 · 40 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 2027
Drug: ROC-101 · For: Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension, Interstitial Lung Disease
Sites: Phoenix, Arizona; Rancho Cordova, California; Aurora, Colorado · 25 sites in all
- Study to Test Effects and Safety of RO7568282 in Early Parkinson's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07781644 · 474 participants (planned) · Start Nov 11, 2026 · Primary completion Dec 15, 2028
Drug: RO7568282; Placebo · For: Parkinson's Disease
Sites: Boca Raton, Florida; Shanghai, China; Cork, Ireland · 6 sites in all
- Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07781657 · 450 participants (planned) · Start Nov 10, 2026 · Primary completion Nov 1, 2029
Drug: RO7568282; Placebo · For: Alzheimer's Disease
Sites: Stuart, Florida; Wellington, Florida; Winter Park, Florida · 12 sites in all
- Study of EVO756 in Adults With MigrainePivotal-lookingRecruiting
Evommune, Inc.Industry
NCT07616128 · 330 participants (planned) · Start Jul 29, 2026 · Primary completion Oct 2027
Drug: EVO756, Dose 1; EVO756, Dose 2 and 1 more · For: Migraine
Sites: Chandler, Arizona; Buena Park, California; Fresno, California · 45 sites in all
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06469944 · 160 participants (planned) · Start Sep 20, 2024 · Primary completion Sep 12, 2029
Drug: Pembrolizumab; Sacituzumab Tirumotecan (sac-TMT) and 6 more · For: Gastroesophageal Junction; Gastroesophageal Adenocarcinoma; Esophageal Neoplasms and 1 more
Sites: Tucson, Arizona; Los Angeles, California; Louisville, Kentucky · 50 sites in all
Vector Y TherapeuticsIndustry
NCT07287397 · 36 participants (planned) · Start Dec 19, 2025 · Primary completion Oct 15, 2027
Drug: Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Diego, California; Jacksonville, Florida · 9 sites in all
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
- A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor FluctuationsPivotal-lookingRecruiting
H. Lundbeck A/SIndustry
NCT07514858 · 150 participants (planned) · Start Jul 28, 2026 · Primary completion Oct 3, 2028
Drug: Lu AF28996; Placebo · For: Parkinson's Disease
Sites: Boca Raton, Florida; Farmington, Michigan; Round Rock, Texas · 6 sites in all
- A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisPivotal-lookingRecruiting
MapLight TherapeuticsIndustry
NCT06887192 · 300 participants (planned) · Start Aug 15, 2025 · Primary completion Dec 2027
Drug: ML-007C-MA; Placebo · For: Psychosis Associated With Alzheimer's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 69 sites in all
BiogenBiogen (BIIB)
NCT07855211 · 69 participants (planned) · Start Oct 7, 2026 · Primary completion Jan 23, 2034
Drug: BIIB147; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Scottsdale, Arizona; St Louis, Missouri; Austin, Texas
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsPivotal-lookingRecruiting
Brise Pharmaceuticals Co., Ltd.Industry
NCT07792681 · 2,079 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2028
Drug: BR005-036C; BR005-036C and 1 more · For: Migraine, With or Without Aura
Sites: Shanxi, China; Inner Mongolia, China; Beijing, China · 81 sites in all
- A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723963 · 260 participants (planned) · Start Sep 18, 2026 · Primary completion Aug 1, 2028
Drug: JZP926 capsule; Placebo · For: Juvenile Myoclonic Epilepsy
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 23 sites in all
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07252739 · 140 participants (planned) · Start Dec 19, 2025 · Primary completion Nov 15, 2029
Drug: MK-1084; Pembrolizumab and 3 more · For: Malignant Neoplasm
Sites: Clermont, Florida; Fargo, North Dakota; Sioux Falls, South Dakota · 40 sites in all
- Trial of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease or Primary TauopathiesPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT07221344 · 160 participants (planned) · Start Nov 18, 2025 · Primary completion Jun 2027
Drug: ARO-MAPT-SC; Placebo · For: Alzheimer Disease; Tauopathies; Frontotemporal Dementia and 1 more
Sites: East York, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
Vima TherapeuticsIndustry
NCT07804615 · 80 participants (planned) · Start Sep 15, 2026 · Primary completion Jun 2027
Drug: VIM0423; VIM0423 Placebo · For: PARKINSON DISEASE (Disorder)
Sites: Scottsdale, Arizona; Murrieta, California; Stamford, Connecticut · 30 sites in all
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPivotal-lookingRecruiting
Reunion Neuroscience IncIndustry
NCT07002034 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2027
Drug: RE104 for Injection · For: Adjustment Disorder
Sites: Birmingham, Alabama; Tucson, Arizona; San Diego, California · 33 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.